Page last updated: 2024-11-05

uridine diphosphate glucose

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uridine Diphosphate Glucose: A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

UDP-alpha-D-glucose : The alpha-anomer of UDP-alpha-D-glucose. It is used in nucleotide sugars metabolism. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID8629
CHEMBL ID375951
CHEBI ID46229
SCHEMBL ID454078
MeSH IDM0022347

Synonyms (68)

Synonym
gtpl1783
uridine 5'-diphospho-alpha-d-glucose
uridine 5'-(trihydrogen pyrophosphate), mono-d-glucosyl ester
uridine 5'-(trihydrogen diphosphate) alpha-d-gucopyranosyl ester
uridine 5'-(trihydrogen pyrophosphate), mono-alpha-d-glucopyranosyl ester (8ci)
uridine pyrophosphate-glucose
uridine 5'-(trihydrogen diphosphate), p'-a-d-glucopyranosyl ester (9ci)
uridine diphosphoglucose
mono-d-glucosyl ester
uridine 5'-(alpha-d-glucopyranosyl pyrophosphate)
uridine 5'-pyrophosphate, alpha-d-glucopyranosyl ester (6ci,7ci)
uridine diphospho-d-glucose
uridine-5'-diphosphate-glucose
uridine 5'-diphosphate glucose
uridine 5-(trihydrogen diphosphate)
133-89-1
uridine diphosphate glucose
UDP-GLUCOSE ,
C00029
udp-alpha-d-glucose
udpg
udpglucose
uridine-5'-monophosphate glucopyranosyl-monophosphate ester
uridine-5'-diphosphoglucose
co-waldenase
5'-diphosphoglucose
cogalactoisomerase
uridine 5'-pyrophosphate glucose ester
co-galactoisomerase
DB01861
uridine diphosphate-glucose
CHEMBL375951
chebi:46229 ,
[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate
bdbm50209659
uridine 5''-[3-alpha-d-glucopyranosyl dihydrogen diphosphate]
udp glucose
einecs 205-121-4
unii-v50k1d7p4y
v50k1d7p4y ,
uridine 5'-(trihydrogen diphosphate), p'-.alpha.-d-glucopyranosyl ester
uridine diphosphate glucose [mi]
uridine diphosphate glucose [who-dd]
cogalactoisomerase [who-dd]
uridine 5'-(trihydrogen diphosphate), p'-.alpha.-d- glucopyranosyl ester
5''''-diphosphoglucose
uridine-5''''-diphosphoglucose
bdbm50423218
SCHEMBL454078
HSCJRCZFDFQWRP-JZMIEXBBSA-N
uridine 5'-[3-alpha-d-glucopyranosyl dihydrogen diphosphate]
DTXSID00157902
uridindiphosphoglucose
udp-glucose disodium salt
(upd)-glucose
uridine 5'-pyrophosphate a-delta-glucopyranosyl ester
uridine 5'-diphospho-alpha-delta-glucose
(udp)glucose
udp-a-d-glucose
uridine diphospho-delta-glucose
udp-delta-glucose
udp-alpha-delta-glucose
uridine 5'-diphospho-a-d-glucose
uridine 5'-pyrophosphate a-d-glucopyranosyl ester
[(2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl dihydrogen diphosphate (non-preferred name)
Q424649
uridine 5/'-(trihydrogen diphosphate), mono-alpha-d-glucopyranosyl ester
AKOS040744389

Research Excerpts

Overview

Uridine diphosphate glucose (UDP-Glc) serves as a glucosyl donor in many enzymatic glycosylation processes. This paper describes a multiple enzyme, one-pot, biocatalytic system for the synthesis of UDP- Glc.

ExcerptReferenceRelevance
"Uridine diphosphate glucose (UDP-Glc) serves as a glucosyl donor in many enzymatic glycosylation processes.This paper describes a multiple enzyme, one-pot, biocatalytic system for the synthesis of UDP-Glc from low cost raw materials: maltodextrin and uridine triphosphate. "( Efficient biosynthesis of uridine diphosphate glucose from maltodextrin by multiple enzymes immobilized on magnetic nanoparticles.
Dong, Q; Ouyang, LM; Xu, JH; Yu, HL, 2010
)
2.1

Toxicity

ExcerptReferenceRelevance
" These novel data highlight the applicability of NMR-based metabonomics in elucidating multicompartmental metabolic consequences of toxicity and toxic salvage."( The mechanism of galactosamine toxicity revisited; a metabonomic study.
Clayton, TA; Coen, M; Holmes, E; Hong, YS; Lindon, JC; Nicholson, JK; Pearce, JT; Reily, MD; Robertson, DG; Rohde, CM, 2007
)
0.34

Bioavailability

ExcerptReferenceRelevance
" This study demonstrates that after the induction of diabetes there is a rapid increase in the bioavailability of substrates utilized in the synthesis of glycoproteins and glycosaminoglycans."( Effects of early diabetes on uridine diphosphosugar synthesis in the rat renal cortex.
Cortes, P; Dumler, F; Levin, NW; Sastry, KS; Verghese, CP, 1982
)
0.26
"Glycosylation is an important method for the structural modification of various flavonols, resulting in the glycosides with increased solubility, stability and bioavailability compared with the corresponding aglycone."( Synthesis of flavonol 3-O-glycoside by UGT78D1.
Fang, Q; Hou, J; Liu, X; Ren, G; Sun, H; Wang, PG; Zhang, L, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
" In cells from fed animals, both the time course and dose-response to glucose of synthase activation were the same in both groups, despite higher levels of phosphorylase a in hepatocytes from obese animals."( Fasting enhances glycogen synthase activation in hepatocytes from insulin-resistant genetically obese (fa/fa) rats.
van de Werve, G, 1990
)
0.28
" Thus, insulin's inhibition of muscle glycogenolysis is the most sensitive insulin action on skeletal muscle and its dose-response characteristics resemble those for the inhibition of hepatic glucose production."( Skeletal muscle glycogenolysis is more sensitive to insulin than is glucose transport/phosphorylation. Relation to the insulin-mediated inhibition of hepatic glucose production.
Hu, M; Rossetti, L, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
UDP-D-glucoseA UDP-sugar having D-glucose as the sugar component.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (22)

PathwayProteinsCompounds
Galactose metabolism ( Galactose metabolism )913
UDP-D-glucose + D-Galactose 1-phosphate = D-Glucose 1-phosphate + UDP-D-galactose ( Galactose metabolism )14
UTP + D-Glucose 1-phosphate = Pyrophosphate + UDP-D-glucose ( Glycolysis and Gluconeogenesis )14
UDP-D-glucose = UDP-D-galactose ( Galactose metabolism )12
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Purinergic signaling053
Glycogen metabolism03
Relationship between glutathione and NADPH036
Ascorbate and aldarate metabolism07
Colanic acid building blocks biosynthesis014
Starch and cellulose biosynthesis09
Glucose-1-phosphate metabolism010
Trehalose anabolism07
Lactose degradation and galactose metabolism07
Glycerol teichoic acid biosynthesis06
Sucrose metabolism1413
Glucose sensing and signaling010
Metabolism overview078
Biochemical pathways: part I0466
Glycogen synthesis and degradation75
Glucuronidation014
Abscisic acid homeostasis216

Protein Targets (3)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)10.00000.00560.682810.0000AID450301
P2Y purinoceptor 6Homo sapiens (human)EC50 (µMol)1.60000.01302.393020.0000AID444562
P2Y purinoceptor 14Homo sapiens (human)EC50 (µMol)80.27300.16000.37650.6700AID1232374; AID286300; AID305271; AID444563; AID450300
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (18)

Processvia Protein(s)Taxonomy
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
phagocytosisP2Y purinoceptor 6Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
activation of phospholipase C activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of smooth muscle cell migrationP2Y purinoceptor 6Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 6Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 6Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 6Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationP2Y purinoceptor 6Homo sapiens (human)
cellular response to pyrimidine ribonucleotideP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor activityP2Y purinoceptor 6Homo sapiens (human)
protein bindingP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UDP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UDP receptor activityP2Y purinoceptor 14Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 6Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 14Homo sapiens (human)
membraneP2Y purinoceptor 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1346914Human GPR17 (Class A Orphans)2010British journal of pharmacology, Mar, Volume: 159, Issue:5
Distinct expression and ligand-binding profiles of two constitutively active GPR17 splice variants.
AID1346857Mouse GPR17 (Class A Orphans)2008PloS one, , Volume: 3, Issue:10
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
AID1346395Rat P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
AID1346390Human P2Y14 receptor (P2Y receptors)2009The Journal of pharmacology and experimental therapeutics, Jul, Volume: 330, Issue:1
Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems.
AID1346389Mouse P2Y14 receptor (P2Y receptors)2001Genomics, Dec, Volume: 78, Issue:3
Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs.
AID1346914Human GPR17 (Class A Orphans)2006The EMBO journal, Oct-04, Volume: 25, Issue:19
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor.
AID531178Activity of Candida albicans 90028 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531172Inhibition of Candida orthopsilosis 981224 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531174Activity of Candida metapsilosis 960161 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531404Activity of Candida albicans 36082 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531175Activity of Saccharomyces cerevisiae BY4742 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531177Activity of Candida albicans Sc5314 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531173Activity of Candida metapsilosis am-2006-0113 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531405Activity of Candida albicans M122 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531170Activity of Candida parapsilosis H5 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531176Activity of Saccharomyces cerevisiae BY4742-FKS1P649A mutant glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531171Activity of Candida orthopsilosis H10 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531169Activity of Candida parapsilosis H4 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID444563Agonist activity at human P2Y14 receptor expressed in HEK293 cells coexpressing phospholipase C-activating Gi protein cells assessed as inhibition of forskolin induced [3H]cAMP production2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.
AID450303Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells up to 10 uM2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID531407Activity of Candida glabrata T51916 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID1232374Agonist activity at recombinant human P2Y14 receptor expressed in African green monkey COS7 cells co-transfected with Galphaqi assessed as stimulation of phospholipase Cbeta2015Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14
Molecular modeling of the human P2Y14 receptor: A template for structure-based design of selective agonist ligands.
AID450300Agonist activity at human P2Y14 receptor expressed in human COS7 cells2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID531168Activity of Candida parapsilosis 22019 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID531406Activity of Candida glabrata 90030 glucan synthase2008Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7
A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.
AID450301Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
AID286300Agonist activity at human P2Y14 expressed in COS7 cells assessed as stimulation of PLC-mediated [3H]inositol hydrolysis2007Journal of medicinal chemistry, May-03, Volume: 50, Issue:9
Structure-activity relationship of uridine 5'-diphosphoglucose analogues as agonists of the human P2Y14 receptor.
AID1137668Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes after 60 mins by liquid scintillation counting2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID305271Agonist activity at human P2Y14 receptor expressed in COS7 cells assessed as stimulation of PLC2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety.
AID444562Agonist activity at human P2Y6 receptor expressed in human 1321N1 cells coexpressing phospholipase C-activating Gq protein assessed as [3H]inositol phosphate production2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,193)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990491 (41.16)18.7374
1990's212 (17.77)18.2507
2000's235 (19.70)29.6817
2010's189 (15.84)24.3611
2020's66 (5.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.34 (24.57)
Research Supply Index7.12 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index91.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.49%)5.53%
Reviews25 (2.03%)6.00%
Case Studies4 (0.32%)4.05%
Observational0 (0.00%)0.25%
Other1,199 (97.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]